Benefit of IQP-VV-102 in Reducing Postprandial Glucose Level in Overweight Caucasian Subjects

NCT02541344 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Prediabetes
Hyperglycemia

Interventions

DEVICE: Dose 1 of IQP-VV-102
DEVICE: Dose 2 of IQP-VV-102
DEVICE: Placebo

Sponsor

InQpharm Group